The FDA received Actavis' application for its Norethindrone Transdermal Delivery System, a progestin-only transdermal contraceptive patch for women, to prevent pregnancy. The acceptance means the filing is complete enough to allow a substantive review, with a goal of acting on the application by the end of the year.

Full Story:
RTT News

Related Summaries